Rotigotine: Transdermal Dopamine Agonist Treatment of Parkinson's Disease and Restless Legs Syndrome

Splinter, Michele Y.

doi:10.1345/aph.1h113

Cited by 62 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Donepezil, pramipexole and L -dopa have also been reported to be effective, though experience is limited to case reports [65, 66]. Restless legs syndrome is readily responsive to DAs [67, 68]. Use of hypnotics should be limited to cases that do not respond to behavioral modifications and other measures, as there are no efficacy data for specific hypnotic agents in PD.…”

Section: Treatment Of Non-motor Symptomsmentioning

confidence: 99%

Treatment of Early Parkinson’s Disease

et al. 2009

View full text Add to dashboard Cite

The management of early Parkinson’s disease (PD) involves the treatment of motor symptoms, and, increasingly, non-motor symptoms. Given the fast pace of clinical research in PD, clinicians are faced with the challenge of integrating the latest findings into the ongoing care of individual PD patients. Part 1 of this 2-part article reviews efficacy and safety data for the newest PD treatment options, as well as for established therapies. Part 2 of the article, presented here, reviews key data relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms.

show abstract

Section: Treatment Of Non-motor Symptomsmentioning

confidence: 99%

Treatment of Early Parkinson’s Disease

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Levodopa's short elimination half-life causes fluctuating plasma concentrations that are closely correlated with motor performance [27]. Rotigotine (Neupro; Schwarz Pharma, Monheim, Germany), a nonergolinic dopamine agonist, is newly approved for treating early-stage idiopathic Parkinson's disease [28]. Neupro is a transdermal delivery system that provides rotigotine continuously over a 24-hour period [29].…”

Section: New Drugs In Psychiatry and Neurologymentioning

confidence: 99%

Pharmacokinetics in geriatric psychiatry

Bigos

Chew

Bies

2008

Curr Psychiatry Rep

View full text Add to dashboard Cite

Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.

show abstract

“…However, the transdermal delivery system bypasses the gastrointestinal system and provides constant systemic levels. Rotigotine is dispersed in a silicone adhesive and spread evenly over the silicone backing of the patch [25]. In a study in which eight healthy volunteers were exposed to rotigotine transdermal patch (2.0 mg/24 h), the median peak plasma concentration was 0.215 ng/ml [26].…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

“…In the liver, rotigotine undergoes extensive metabolism by means of conjugation (sulfation, glucuronidation) or catalysis by the P450 cytochrome system [25]. Inactive metabolites are excreted primarily in urine (∼ 71%) and to a lesser degree in feces [30][31][32].…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome

Kenney

Jankovic

2007

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Dopamine agonists are effective in delaying levodopa-induced dyskinesia in early Parkinson's disease (PD) and reducing motor fluctuations in advanced PD. Rotigotine, a novel dopamine receptor agonist, improves motor function in both early and advanced PD using a transdermal route of administration. A smaller, but convincing body of data, supports its ability to ameliorate the symptoms of restless legs syndrome as well. The side-effect profile mimics other dopamine agonists, with the addition of application-site reactions, most of which are mild-to-moderate. Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties.

show abstract

Rotigotine: Transdermal Dopamine Agonist Treatment of Parkinson's Disease and Restless Legs Syndrome

Abstract: Longer trials are required to determine whether transdermal rotigotine will reduce development of dyskinesias and motor fluctuations in Parkinson's disease and augmentation and rebound in RLS by preventing pulsatile dopamine stimulation associated with levodopa and other dopamine agonists.

Cited by 62 publications

References 23 publications

Treatment of Early Parkinson’s Disease

Treatment of Early Parkinson’s Disease

Pharmacokinetics in geriatric psychiatry

Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome

Contact Info

Product

Resources

About